Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01993719 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Cyclophosphamide
DRUG: Cyclophosphamide
BIOLOGICAL: Young TIL
DRUG: Pembrolizumab

Sponsor

National Cancer Institute (NCI)